Abstracts tagged "ANCA"

Abstract Number: 0727 • ACR Convergence 2025
Higher rates of severe sensorineural hearing loss in granulomatosis with polyangiitis (GPA) compared to other antineutrophil cytoplasmic antibody (ANCA) associated vasculitis
Sehreen Mumtaz¹, Kindalem Fentie², Joseph Parker², Emily Craver¹, Vikas Majithia³ and Andy Abril⁴, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Mayo Clinic Hospital, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville
Background/Purpose: Hearing loss in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is one of the commonly reported manifestations of organ damage in AAV with predominantly…
Abstract Number: 0728 • ACR Convergence 2025
Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
Susana Romero-Yuste¹, Marta Domínguez-Álvaro², Antonio Fernández-Nebro³, Miquel Blasco⁴, Beatriz Ventosa⁵, Javier Narváez⁶, Gema Fernández⁷, Iñigo Rúa-Figueroa⁸, Desirée Luis-Rodríguez⁹ and Manuel Macía¹⁰, ¹University Hospital Complex of Pontevedra, Pontevedra, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ⁴Hospital clinic Barcelona, Barcelona Spain, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital la Paz, Madrid, Madrid, Spain, ⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁹Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain, ¹⁰Hospital Universitario Nuestra Señora de Candelaria,, Tenerife, Spain
Background/Purpose: ANCA-associated vasculitides (AAV)—granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA)are rare but severe systemic vasculitides with significant morbidity and…
Abstract Number: 0724 • ACR Convergence 2025
Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
Milad Heydari-Kamjani¹, Elleson Harper² and Haseeb Chaudhary³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³Case Western Reserve University, Westlake, OH
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune vasculitis. Avacopan, a novel oral C5a receptor inhibitor, has emerged as an adjunct therapy…
Abstract Number: 0150 • ACR Convergence 2025
Mortality in Anca-associated Vasculitis
Fabricio Benavides Villanueva¹, Vanesa Calvo-Río², Diana Prieto-Peña³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁸, maria Rodríguez-Vidriales⁸ and Ricardo Blanco², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Mortality rates are scare,…
Abstract Number: 2516 • ACR Convergence 2025
Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)
Rameez Qasim¹, Sabah Mohib², Muhammad Ali³ and Khadija Mohib⁴, ¹Allama Iqbal Medical College Lahore, Lahore, Pakistan, ²N/A, Reseda, CA, ³Dow International Medical College, Karachi, Sindh, Pakistan, ⁴Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV
Background/Purpose: Primary systemic vasculitides comprise a group of immunological disorders that inflame blood vessel walls and are categorized by the size of the blood vessels…
Abstract Number: 2504 • ACR Convergence 2025
Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Anuya Natu¹, Isadora Small², Shilpa Arora³ and Augustine Manadan⁴, ¹John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ²The Latin School of Chicago, Chicago, IL, ³Cook County Hospital, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis that can lead to significant morbidity and mortality. This study aims to evaluate the…
Abstract Number: 1912 • ACR Convergence 2025
Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort
Robert Micheletti¹, William Song¹, Brian Chu², Lynne Allen-Taylor³, Joel Gelfand³, Peter Grayson⁴, Cristina Ponte⁵, Joanna Robson⁶, Ravi Suppiah⁷, Raashid Luqmani⁸, Richard Watts⁹ and Peter Merkel¹⁰, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Brown University Health, Providence, RI, ³University of Pennsylvania, Philadelphia, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁵Unidade Local de Saúde de Santa Maria, Lisbon, Portugal, ⁶University of the West of England Bristol, Bristol, United Kingdom, ⁷Health New Zealand - Te Toka Tumai, Auckland, New Zealand, ⁸University of Oxford, Oxford, United Kingdom, ⁹University of East Anglia, Norwich, United Kingdom, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vasculitis is a group of rare, multisystem diseases which may involve the skin. Characterization of the frequency, type, and significance of cutaneous manifestations in…
Abstract Number: 1693 • ACR Convergence 2025
Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
Laura van Dam¹, Mengrui Zhang¹, Shima Parsafar², Audra Horomanski³, Sajede Rasouli², Orr Sharpe², Jolijn van Leeuwen⁴, Tobias Lanz², Cees van Kooten⁴, Onno Teng⁵ and William H. Robinson³, ¹Stanford University, Stanford, CA, ²Stanford University, Stanford, ³Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease, characterized by ANCAs targeting myeloperoxidase (MPO) or proteinase-3 (PR3). ANCA-specific B cells have…
Abstract Number: 1605 • ACR Convergence 2025
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol-Frigole⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins-Martinho¹⁰, Camillo Ribi¹¹, Mathieu Groh¹² and Benjamin Terrier¹³, ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²Sechenov University, Moscow, Russia, ³University of Padova, Padova, Italy, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁷CHU Toulouse, Toulouse University, Toulouse, France, ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ¹⁰ULS Santa Maria, Lisbon, Portugal, ¹¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ¹²Hôpital Foch, Suresnes, France, ¹³Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
Abstract Number: 1597 • ACR Convergence 2025
Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
Caitlyn Kanters¹, Joo Young Lee², Christian Pagnoux³, Lillian Barra⁴, Jean-Paul Makhzoum⁵ and Arielle Mendel⁶, ¹McGill University, Montreal, Canada, ²Research institute of the McGill University Health Center, Montreal, QC, Canada, ³Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁴Western University, London, ON, Canada, ⁵University of Montreal, Montreal, ⁶McGill University Health Centre, Montreal, Canada
Background/Purpose: To evaluate the safety and effectiveness of rituximab biosimilars in the treatment of small vessel vasculitis.Methods: The Medline, CINAHL, Cochrane, Embase and Web of…
Abstract Number: 1162 • ACR Convergence 2025
Antineutrophil cytoplasmic antibody-associated isolated interstitial lung disease
Javier Narváez¹, Pol Maymó-Paituvi², Vanesa Vicens Zygmunt³, Guadalupe Bermudo⁴, Martí Aguilar-Coll⁵, Montserrat Roig Kim², Laia De Daniel Bisbe², Joan Miquel Nolla² and Maria Molina-Molina⁴, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ³Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁵Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: There is increasing evidence of the association between interstitial lung disease (ILD) and ANCA positivity without other manifestations of systemic vasculitis. The prognosis of…
Abstract Number: 0715 • ACR Convergence 2025
Supervised machine learning algorithm to identify patients with eosinophilic granulomatosis with polyangiitis in France
Benjamin Terrier¹, Solenne Tauty², Anouar Salhi², Francoise Bugnard², Steve Benard², Vincent Cottin³, Camille Taillé⁴ and Xavier Puéchal⁵, ¹Cochin Hospital, Paris, France, ²Steve Consultants, Lyon, France, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Bichat hospital, APHP, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France
Background/Purpose: Identifying patients with eosinophilic granulomatosis with polyangiitis (EGPA) in claims databases such as the French National Health Data System (SNDS) is a major challenge…
Abstract Number: 0725 • ACR Convergence 2024
Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Lucy Eunju Lee¹, Taejun Yoon², Yong-Beom Park² and Sang-Won Lee², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…
Abstract Number: 2492 • ACR Convergence 2024
ANCA Associated Tracheobronchial Disease
Megan Sullivan¹, Maximiliano Diaz Menindez², Ronald Butendieck³, hassan baig⁴, Anushka Irani⁵, Benjamin Wang³, Florentina Berianu⁵, Carolyn Mead-Harvey⁶, Andy Abril⁵ and Vikas Majithia⁴, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic, Ponte Vedra Beach, FL, ⁶Mayo Clinic, Scottsdale, AZ
Background/Purpose: Tracheobronchial disease is a common manifestation of ANCA associated vasculitis (AAV). However, outcomes data is commonly unreported in prospective studies. We performed a retrospective…
Abstract Number: 0726 • ACR Convergence 2024
Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review
Emma Neary¹, Katie Healey², Marie Clements-Baker³, Jean-Paul Makhzoum⁴ and Arielle Mendel⁵, ¹McGill University, Montreal, QC, Canada, ²Memorial University of Newfoundland, St. John's, NL, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains…

1
2
3
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].